【摘要】 目的观察低分子肝素作为抗凝剂在血液透析串联血液灌流治疗中的有效性及安全性。方法 35例维持规律透析及急性中毒需接受血液透析串联血液灌流治疗的患者,采用低分子肝素钠为抗凝剂,观察透析器、灌流器、管道凝血情况,在治疗中后观察是否有凝血、出血或加重出血、穿刺点压迫所需时间。观察在血液灌流中的疗效及安全性,并初步探讨其用法及用量。结果所有患者均顺利完成治疗,共完成362例次,灌流器凝血发生率为0.55%(2/362),透析器凝血发生率为3.87%(14/362)。透析后压迫止血时间为(12±5)min,无一例患者治疗后诱发出血。结论低分子肝素作为抗凝剂应用于血液透析串联血液灌流治疗中的抗凝效果显著,其更为安全、高效、可靠。更多还原

【Abstract】 Objective To observe effectiveness and safety by low molecular weight heparin as anticoagulation in hemodialysis combined with hemoperfusion. Methods A total of 35 patients received low molecular weight heparin as anticoagulation in hemodialysis combined with hemoperfusion for treatment of maintenance regular dialysis and acute poisoning. Observation was made on dialyzer, perfusion device, pipeline coagulation, coagulation, hemorrhage or aggravated hemorrhage during treatment, pressure time on puncture point, curative effect and safety in hemoperfusion, in order to investigate its application method and dosage. Results All patients received successful treatment for 362 times. Incidence of perfusion device coagulation was 0.55%(2/362), and incidence of dialyzer coagulation was 3.87%(14/362). Compression hemostasis time after hemodialysis was(12±5) min. There was no case with induced bleeding after treatment. Conclusion Implement of low molecular weight heparin as anticoagulation in hemodialysis combined with hemoperfusion shows excellent anticoagulation effect. This method is safe, efficient and creditable.更多还原